Avonex

CHMP backs European approval for six new medicines

Avonex (interferon beta-1a) on track for approval in mid-2014. ... Plegridy requires less frequent injections than Avonex and is administered subcutaneously rather than intramuscularly, so should be less painful for patients.

Sales down at Merck Serono on Rebif pressure

which was overshadowed by exchange rate factors and the loss of 30m-worth of royalty income on sales of Biogen Idec's MS drug Avonex (interferon beta-1a) in the quarter.

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Avonex (interferon beta-1a) slipped slightly to $733m in the third quarter but gained market share in the injectable MS therapy segment. ... There was mixed news for Biogen Idec's R&D pipeline, however. A pegylated version of Avonex called Plegridy could

Biogen Idec's long-acting beta interferon moves ahead in MS

The benefits of Plegridy are that it will require less frequent injections than Avonex and will be administered subcutaneously rather than intramuscularly, so should be less painful. ... The new product is given once every two or four weeks, while Avonex

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales. Solid growth of Biogen Idec's multiple sclerosis (MS) drugs Tysabri and Avonex helped lift the company's fourth quarter revenues by 7 per ... Tysabri (natalizumab) continued its run of growth with a 10 per cent

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]